Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites by Atsushi Goto et al.
CASE REPORT
Re-response to tolvaptan after furosemide dose reduction
in a patient with refractory ascites
Atsushi Goto • Shuji Terai • Munetaka Nakamura •
Masaharu Matsumoto • Isao Sakaida
Received: 16 September 2014 / Accepted: 20 November 2014 / Published online: 5 December 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Tolvaptan is a new drug used for treating
ascites induced by liver cirrhosis, and it is covered by
health insurance in Japan. In the present report, we describe
the case of a 74-year-old man with type C liver cirrhosis
and refractory ascites. He was receiving furosemide and
spironolactone daily, but still required repeat puncture for
ascites removal. Administration of tolvaptan (3.75 mg/day)
was started in addition to his existing medications, and was
subsequently increased to 7.5 mg/day. However, after
2 months, the ascites again exacerbated. Nevertheless, after
we discontinued the administration of furosemide, the
tolvaptan became effective. This may be because furose-
mide administration decreases urine osmolality, resulting
in a non-response to tolvaptan.
Keywords Tolvaptan  Vasopressin V2-receptor
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Introduction
The selective vasopressin V2-receptor antagonist tolvaptan
is a newly introduced diuretic, and has a different mecha-
nism as compared with conventional loop diuretics [1]; in
Japan, it has been used for fluid retention in heart failure
patients since 2010. In 2013, it was approved for treating
fluid retention associated with liver cirrhosis (in doses up to
7.5 mg/day). Tolvaptan is an option for managing body
fluid in liver cirrhosis patients who have been managed by
furosemide and/or spironolactone, and it has great potential
for treating patients with a refractory condition. However,
many issues remain unclear, including the combined
method for using it with existing drugs, dosing period, and
prerequisites for obtaining favorable outcomes. In the
present report, we describe a case of refractory ascites
associated with type C liver cirrhosis wherein a complete
response was achieved immediately after administering
tolvaptan; however, the ascites exacerbated after 2 months,
and the drug’s diuretic effect was restored by discontinuing
furosemide.
Case report
A 74-year-old man presented to our hospital with abdom-
inal pain and bloating since December 2013. He had
undergone craniotomy for a brain tumor approximately
30 years ago. He had no history of alcohol consumption or
cigarette smoking, and his family history was not signifi-
cant. Since 2001, he had been managed regularly for
type C liver cirrhosis. He did not have a treatment history
of interferon use. He had undergone sclerotherapy for
esophageal varices in 2001 and hepatic arterial chemo-
embolization in 2004, and did not have any recurrences.
However, he continued to receive oral furosemide (20 mg)
and spironolactone (50 mg) daily for ascites retention.
Although he maintained a body weight of 60 kg and an
abdominal circumference of 85 cm, his body weight and
abdominal circumference rapidly increased to 70 kg and
100 cm, respectively. Ultrasound confirmed the presence
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of increased ascites; thus, the dose of furosemide was
increased to 30 mg/day, and puncture was repeated for
ascites removal. Since there was no improvement, he was
hospitalized in January 2014.
On admission, the following physical findings were
noted: height, 168 cm; body weight, 69 kg; abdominal
circumference, 100 cm; consciousness, lucid; body tem-
perature, 35.5 C; blood pressure, 137/85 mmHg; pulse, 80
beats/min (regular). The palpebral conjunctiva showed no
sign of anemia. The bulbar conjunctiva had no yellow
staining. The chest findings were normal with no evidence
of heart murmur or spider angioma. The abdomen was
swollen, severely distended, and wave-palpable. He had
spontaneous abdominal pain without tenderness and had no
edema in the extremities.
His blood test findings are shown in Table 1. The Child–
Pugh score was 9 points (B) with moderate or greater
ascites volume and no encephalopathy. His platelet count
was low. No renal impairment was observed.
On plain abdominal computed tomography (Fig. 1),
both the hepatic lobes were atrophic with a blunt margin
and irregularity on the surface. A moderate volume of
ascites retention was observed.
The ascites fluid obtained following puncture indicated
the presence of transudative ascites, which was macro-
scopically pale yellow and transparent with a cell count of
200/lL and a protein level of 2.0 g/dL. The cytological
diagnosis was class I, and the culture test was negative.
The patient’s clinical course is presented in Fig. 2. The
patient was on salt restriction (B5 g/day) and water
restriction (B1 L/day), and he underwent three courses of
cell-free and concentrated ascites reinfusion therapy
(CART). However, he again exhibited ascites retention
after several days, and the urinary volume was insufficient
at 1,000–1,500 mL/day. On day 10, oral tolvaptan
(3.75 mg/day) was started, and his urinary volume imme-
diately increased to 2,000 mL/day. Adverse reactions, such
as hypernatremia and liver dysfunction, were not observed.
Since the patient still required puncture for ascites removal,
the dose of tolvaptan was increased to 7.5 mg/day on
day 17. His urinary volume increased to approximately
2,500 mL/day, and his body weight and abdominal cir-
cumference improved gradually without any puncture for
ascites removal. His abdominal pain and bloating
improved, and he was discharged on day 22.
He continued tolvaptan (7.5 mg/day) treatment, and at
approximately day 60, the patient realized that his urinary
volume had decreased. He presented with abdominal
bloating and weight gain again. Re-exacerbation of the
ascites was suspected, and the patient was readmitted on
day 72 (Fig. 3). A sufficient urinary volume was not
observed after admission. We presumed that urine osmo-
lality decreased due to the continuous administration of
furosemide, which may have hampered the diuretic effect of
tolvaptan in the renal collecting tubule; furosemide was
discontinued on day 78. Subsequently, his urinary volume
temporarily increased to more than 4,000 mL/day. There is a
possibility that the albumin infusions (days 78–80) affected
the temporary increase in his urinary volume; however, a
Table 1 The patient’s laboratory data on admission
Biochemistry Hematology
TP 6.8 mg/dL WBC 1,800/lL
ALB 2.4 mg/dL RBC 357 9 104/lL
T-bil 1.30 mg/dL Hb 12.2 g/dL
D-bil 0.35 mg/dL Plt 4.0 9 104/lL
AST 64 IU/L Virus marker
ALT 60 IU/L HBs Ag (-)
ALP 311 IU/L HCV Ab (?)
c-GTP 28 IU/L Urine examination
BUN 11.0 mg/dL Specific gravity 1.010
Cre 0.81 mg/dL pH 6.5
Na 144 mEq/L Protein (-)
K 2.9 mEq/L Glucose (-)
Cl 108 mEq/L Occult blood (-)
eGFR 71 mL/min/1.73 m2 Ketone (-)
Coagulation Urobilinogen Normal
PT 70.3 % Bilirubin (-)
TP total protein, ALB albumin, T-bil total bilirubin, D-bil direct bil-
irubin, AST aspartate aminotransferase, ALT alanine aminotransfer-
ase, ALP alkaline phosphatase, c-GTP gamma-glutamyl
transpeptidase, BUN blood urea nitrogen, Cre creatinine, Na sodium,
K potassium, Cl chloride, eGFR estimated glomerular filtration rate,
PT prothrombin time, WBC white blood cells, RBC red blood cells,
Hb hemoglobin, Plt platelets, HBs Ag hepatitis B core antigen, HCV
Ab hepatitis C virus core antigen
Fig. 1 Plain abdominal computed tomography image. The hepatic
lobes are atrophic with a blunt margin and irregularity on the surface.
A moderate volume of ascites retention is also observed
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volume of C2,000 mL/day was maintained over the next
month after discontinuing furosemide. The urine osmolality
immediately increased from 300 to 650 mOsm/L after dis-
continuing furosemide. In addition, 3 days after discon-
tinuing furosemide (day 81), the urine osmolality decreased
to 365 mOsm/L. The abdominal symptoms, body weight,
and abdominal circumference returned to their original
levels. Tolvaptan was continued (7.5 mg/day) without
exacerbation of the ascites. The serum sodium level was
maintained (range 139–144 mEq/L) throughout the course.
Fig. 2 The patient’s clinical
course after the first admission
Fig. 3 The patient’s clinical
course after the second
admission
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Discussion
The use of existing natriuretic agents for treating ascites
associated with liver cirrhosis is problematic for the fol-
lowing reasons: hyponatremia is likely to occur; diuresis
resistance or impaired renal function is induced by the
activation of the renin–angiotensin–aldosterone system;
and hypoalbuminemia-associated treatment resistance may
occur. Tolvaptan acts on the renal collecting tubule,
inhibits the reabsorption of water, and accelerates urinary
excretion [1]. Since it results in the excretion of only free
water without inducing natriuresis, tolvaptan improves
hyponatremia [2]. Moreover, it does not affect the activa-
tion of the renin–angiotensin–aldosterone system, thereby
allowing the body fluid to be controlled without impairing
renal function [3]. According to Japanese and overseas
large-scale clinical studies, it exhibits a diuretic effect and
improves clinical symptoms in heart failure patients [4, 5].
Thuluvath et al. [6] reported that the administration of a
vasopressin V2-receptor antagonist in addition to conven-
tional treatment with furosemide and spironolactone
increased urinary volume in liver cirrhosis patients. Okita
et al. [7] first reported the results of a randomized, double-
blind, placebo-controlled study on tolvaptan for refractory
ascites associated with liver cirrhosis. When tolvaptan was
administered to patients with hepatic edema at dosages of
30, 15, or 7.5 mg/day for 7 days, the maximum decrease in
weight and abdominal circumference was observed in
patients receiving 7.5 mg/day, thus providing the basis for
the current upper dose limit in the present case. Sakaida
et al. [8] reported that the weight loss obtained by short-
term treatment with diuretics in liver cirrhosis patients
strongly correlated with the volume of ascites, accounting
for approximately 30 % of cases with weight loss. More-
over, in a randomized, double-blind, placebo-controlled
study, they reported that a significant weight loss was
obtained in patients receiving 7.5 mg/day of tolvaptan,
revealing that it is effective for improving ascites [9]. They
also reported that it is useful for treating patients with
hypoalbuminemia (serum albumin level \2.5 g/dL),
because of tolvaptan’s effect on the renal collecting tubule
through the blood flow.
Although tolvaptan is expected to play an innovative
role in treating refractory patients, no diuresis is achieved
even after administration, and the efficacy of this drug can
often be diminished, as seen in the present case. An
approach to determine its appropriate use involves the
elucidation of the responders to this drug. One possible
approach is to use urine osmolality as a marker reflecting
the function and activity of the renal collecting tubule.
Imamura et al. [10] defined patients with heart failure who
had an increase in urinary volume during 24 h after the
start of tolvaptan administration as responders, revealing
that responders showed a significant improvement in body
weight, brain natriuretic peptide levels, and clinical
symptoms. Moreover, they reported that the predictive
factors of responders are urine osmolality of C352 mOsm/
L before tolvaptan administration or a C26 % urine
osmolality reduction at 4–6 h after administration [11–13].
The mechanism of water reabsorption by vasopressin is as
follows: the binding of vasopressin to V2-receptors in the
renal collecting tubule induces cyclic adenosine mono-
phosphate dependent synthesis of the aquaporin-2 water
channel and its migration to the cellular surface, which in
turn leads to increased water permeability in the collecting
tubule, thus resulting in enhanced water reabsorption
mediated by an osmotic pressure gradient formed between
the hypotonic urine in the collecting tubule and the
hypertonic renal interstitium [14]. Tolvaptan competitively
inhibits V2-receptor binding, thereby suppressing the
expression of aquaporin-2 and inducing water diuresis.
Patients who initially have a low urine osmolality may
have a decreased expression of aquaporin-2 or a reduced
osmotic pressure gradient, thus making it difficult for tol-
vaptan to be efficacious [11].
The urine osmolality increased from 300 to 650 mOsm/
L after discontinuing furosemide in our patient. The urine
osmolality should be evaluated before starting tolvaptan.
Although the urine osmolality was originally at the level
where an effective water diuretic effect could not be
obtained, discontinuing furosemide may have increased
urine osmolality in the medullary collecting tubule to the
range where tolvaptan is effective, thereby achieving
diuresis. In addition, 3 days after discontinuing furose-
mide, the urine osmolality decreased to 365 mOsm/L; thus,
the urine osmolality may have decreased because of the
sufficient water diuresis caused by tolvaptan. Since the
maximum dose of tolvaptan has already been used, it is
important to review its preparation by evaluating the
osmolality of concomitant diuretic agents.
Our case is valuable, because a non-responder became a
responder by adjusting a loop diuretic. The maximum dose
of tolvaptan is 7.5 mg/day. However, if 7.5 mg of tolvap-
tan is administered and the patient’s urine volume
decreases, the doctor may assume that this effect is a result
of another diuretic. In our case, furosemide decreased the
osmolality; therefore, we recommend that clinicians assess
the osmolality and reconsider the decreasing effect of other
diuretics. Similarly, Imamura et al. [15] reported that a
patient with acute renal impairment did not respond to the
initial administration but responded to tolvaptan when the
renal impairment resolved and renal osmolality was
increased. The diuretic effect of tolvaptan can be enhanced
by considering the administration timing and by adjusting
concomitant conventional diuretic agents. Although the
appropriate dosing period for tolvaptan in patients with
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hepatic edema is unclear, there is a potential diminished
effect after long-term administration. A future study on
long-term users is needed to establish the efficacy of
tolvaptan.
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